Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Trulieve Cannabis (TCNNF) Non-Current Debt (2020 - 2025)

Trulieve Cannabis has reported Non-Current Debt over the past 6 years, most recently at $90.8 million for Q4 2025.

  • Quarterly results put Non-Current Debt at $90.8 million for Q4 2025, down 18.85% from a year ago — trailing twelve months through Dec 2025 was $90.8 million (down 18.85% YoY), and the annual figure for FY2025 was $90.8 million, down 18.85%.
  • Non-Current Debt for Q4 2025 was $90.8 million at Trulieve Cannabis, down from $107.7 million in the prior quarter.
  • Over the last five years, Non-Current Debt for TCNNF hit a ceiling of $115.9 million in Q4 2023 and a floor of $1.3 million in Q2 2021.
  • Median Non-Current Debt over the past 5 years was $93.5 million (2023), compared with a mean of $73.0 million.
  • Biggest five-year swings in Non-Current Debt: surged 2606.2% in 2023 and later dropped 18.85% in 2025.
  • Trulieve Cannabis' Non-Current Debt stood at $6.5 million in 2021, then surged by 1359.84% to $94.2 million in 2022, then grew by 22.93% to $115.9 million in 2023, then dropped by 3.37% to $111.9 million in 2024, then dropped by 18.85% to $90.8 million in 2025.
  • The last three reported values for Non-Current Debt were $90.8 million (Q4 2025), $107.7 million (Q3 2025), and $108.5 million (Q2 2025) per Business Quant data.